Slides
Page 1
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2025. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its affiliates. No part of it may be used, circulated, quoted, or reproduced for distribution outside companies belonging to the Eurofins Group. If you are not the intended recipient of this document, you are hereby notified that the use, circulation, quoting, or reproducing of this document is strictly prohibited and may be unlawful. Photo images on this page are the copyrighted property of 123RF Limited. D www.eurofins.com 2025 North America Investor Day Lancaster 13 November 2025
Page 2
2 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Disclaimer This presentation does not constitute or form part of, and should not be construed as, an offer or invitation to subscribe for or purchase securities in Eurofins Scientific S.E. and neither this document nor anything contained or referred to in it shall form the basis of, or be relied on in connection with, any offer or commitment whatsoever. The statements made during this presentation or as response to questions during the Question & Answers period that are not historical facts are forward looking statements. Furthermore, estimates and judgements may be made based on market and competitive information available at a certain time. Forward looking statements and estimates represent the judgement of Eurofins Scientific’s management and involve risks and uncertainties including, but not limited to, risks associated with the inherent uncertainty of research, product/service development and commercialisation, the impact of competitive products and services, patents and other risk uncertainties, including those detailed from time to time in period reports, including prospectus and annual reports filed by Eurofins Scientific with the Luxembourg Stock Exchange and regulatory authorities, that can cause actual results to differ materially from those projected. Eurofins Scientific expressly disclaims any obligation or intention to release publicly any updates or revisions to any forward-looking statement or estimate. Eurofins provides in the Income Statement certain alternative performance measures (non-IFRS information as “Adjusted Results and Separately Disclosed Items”) that exclude certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. (Please refer to description of these terms in the company’s Annual Report). The management believes that providing this information enhances investors' understanding of the company’s core operating results and future prospects, consistent with how management measures and forecasts the company’s performance, especially when comparing such results to previous periods or objectives and to the performance of our competitors. This information should be considered in addition to, but not in lieu of, information prepared in accordance with IFRS. These APMs are described in more detail in the Consolidated Financial Statements 2024 in Notes 1.20 and 1.21. Alternative Performance Measures (APMs) are defined at the end of this presentation.
Page 3
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2025. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its affiliates. No part of it may be used, circulated, quoted, or reproduced for distribution outside companies belonging to the Eurofins Group. If you are not the intended recipient of this document, you are hereby notified that the use, circulation, quoting, or reproducing of this document is strictly prohibited and may be unlawful. Photo images on this page are the copyrighted property of 123RF Limited. D www.eurofins.com CEO Presentation Dr Gilles Martin Chairman and Chief Executive Officer
Page 4
4 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Eurofins: The World Leader in Testing for Life 450,000,000+ tests performed each year 200,000+ validated analytical methods 65,000+ employees 950+ laboratories 60 active countries • Long-term track record of turning investments into growth, productivity, margin expansion and Return on Capital Employed • Competitive advantages based on scale and one-of-a-kind fully digital ‘hub and spoke’ laboratory network infrastructure • Well positioned for the future in terms of technological capabilities, scientific expertise and innovation power • Committed to sustainability and ESG Key Figures 35+ years of value creation
Page 5
5 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Eurofins' performance in 2024 demonstrated resumption of pre-COVID historic profit and cash flow growth trends 1 FCFF/Rep. EBITDA 2 Free Cash Flow to Equity less earnings paid to hybrid capital investors 3Affected by June 2019 cyber-attack Profitability Cash Flow 20193 2020 2021 2022 2023 2024 Δ 20193 to 2024 CAGR 20193- 2024 Cash conversion1 43% 65% 56% 35% 38% 56% +1,300bps - NWC intensity (%) 5.3% 4.5% 4.5% 4.2% 5.1% 3.8% -150bps - FCFF (m€) 359 873 1,030 491 474 801 +123% +17% FCF to shareholders2 (m€) 88 621 665 244 183 457 +419% +39% FCF to shareholders2/share (€) 0.49 3.34 3.47 1.27 0.95 2.40 +390% +37% 20193 2020 2021 2022 2023 2024 Δ 20193 to 2024 CAGR 20193- 2024 Revenues (m€) (COVID revenues) 4,563 5,439 (~€800m) 6,718 (~€1,400m) 6,712 (~€600m) 6,515 6,951 +52% +9% Adj. EBITDA (m€) 931 1,413 1,902 1,513 1,364 1,552 +67% +11% Adj. EBITDA margin (%) 20.4% 26.0% 28.3% 22.5% 20.9% 22.3% +190bps - Rep. EBITDA (m€) 833 1,351 1,840 1,415 1,234 1,439 +73% +12% Rep. EBITDA margin (%) 18.3% 24.8% 27.4% 21.1% 18.9% 20.7% +240bps - Rep. Basic EPS 0.82 2.71 3.91 3.02 1.33 1.87 +128% +18% Period impacted by COVID-19
Page 6
6 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Trajectory continuing in 2025, demonstrating progress to our target financial profile In €m except otherwise stated H1 2024 H1 2025 +/- % Revenues 3,419 3,612 +5.7% Organic Growth +3.9%1 Adjusted EBITDA 757 810 +7.0% Adjusted EBITDA margin2 22.1% 22.4% +30bps Reported EBITDA 714 773 +8.3% Reported EBITDA margin 20.9% 21.4% +50bps Reported Basic EPS (€) 1.01 1.20 +18% Net working capital intensity 6.3% 5.5% -80bps Capex/Revenues 7.4% 6.9% -50bps On track for organic growth guidance of mid-single- digit in 2025, with expected acceleration in H2 Profit growth ahead of revenue, from adjusted EBITDA margin expansion and lower SDIs Leverage throughout the P&L, supported by efficient balance sheet and share count reduction Moving to sustainably lower cost of growth, as major network investments complete across the portfolio Key figures 1 2.9% excluding adjustment for public working days 2 Adjusted EBITDA divided by reported revenues
Page 7
7 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Continued strong secular growth outlook in all Eurofins activities Activities Revenue share in H1 2025 Growth drivers Organic growth outlook Life • Food and Feed Testing • Agro Testing • Environment Testing ~40% • Rising awareness and demand for food safety & quality and contamination & pollution issues • Increasing regulations requiring more stringent and sophisticated analyses Around Eurofins average BioPharma • BioPharma Services • Agrosciences • Genomics • Forensic Services ~30% • Need for pharma companies to expand new drug pipelines • Rapid technological change & increasing complexity in testing for biologics and ATMPs require ongoing investment in technology & expertise Above Eurofins average Diagnostic Services & Products • Clinical Diagnostics Testing • In Vitro Diagnostics (IVD) Solutions ~20% • Demographics driving healthcare spending • Medical, technological and scientific innovation • Personalised medicine offering patients individualised treatments based on their genetic and metabolic profiles Slightly below Eurofins average Consumer & Technology Products Testing • Consumer Product Testing • Advanced Material Sciences ~10% • Focus on products that can have a direct impact on health (cosmetics, textiles, medical devices, electronics, etc.) • Development of new materials for advanced applications Around Eurofins average Long-term objective: 6.5% p.a. average organic growth + €250m p.a. revenues from acquisitions
Page 8
8 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 0% 10% 20% 30% 40% 2019 2020 2021 2022 2023 2024 Europe is starting to close the profitability gap – further opportunities from network leverage and IT costs in spite of significant start-up costs Europe North America Rest of the World 1 Not adjusted for estimated cyber-attack impact 2 Improvement in 2020 and 2021 margins due to temporarily very high COVID testing levels 2024 progress delivered: • Price increases across most countries and segments to catch up some of 2022/2023 inflation, along with volume growth and cost discipline • Absorbed headwind from tariff cuts in September 2024, in France Clinical Diagnostics routine clinical testing 0% 10% 20% 30% 40% 2019 2020 2021 2022 2023 20241 1 Reported EBITDA margin Reported EBITDA margin 0% 10% 20% 30% 40% 2019 2020 2021 2022 2023 2024 1 Reported EBITDA margin 2024 progress delivered: • Leverage from strong volume growth in Environment and Food testing, and sustained price increases to catch up inflation • Controlled personnel and consumables costs 2024 progress delivered: • Biggest volume growth contributions from Australia, China and Taiwan, with controlled personnel costs • Margins in Asia-Pacific and Middle East accretive to the Group in 2024 2 2 2 2 2 2 COVID revenue peak COVID revenue peakCOVID revenue peak Priorities to 2027: • Completion of best-in-class hub and spoke network for Food Testing and Environment Testing • Reduce IT costs, currently ~300bps above Group as % of sales - key projects to complete by 2027 include IT infrastructure rebuild in modern isolated zones, new suite of bespoke IT solutions, replacing legacy systems Priorities to 2027: • Leverage of already complete hub and spoke networks, with low incremental cost of growth in both headcount and investment Priorities to 2027: • Continuation of volume growth and disciplined cost management
Page 9
9 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Headwind from recent investments also reducing as non-mature assets ramp (€m) FY 2023 FY 2024 H1 2025 FY 2023 FY 2024 H1 2025 FY 2023 FY 2024 H1 2025 Revenues 6,189 6,555 3,361 325 396 251 6,515 6,951 3,612 Reported EBITDA 1,326 1,511 793 -92 -71 -20 1,234 1,439 773 % of revenues 21.4% 23.0% 23.6% -28.2% -18.0% -8.0% 18.9% 20.7% 21.4% EBITDA impact from SDIs1 -38 -42 -17 -92 -71 -20 -129 -113 -37 % of revenues -0.6% -0.6% -0.5% -28.2% -18.0% -8.0% -2.0% -1.6% -1.0% Adjusted EBITDA 1,364 1,552 810 - - - 1,364 1,552 810 % of revenues2 22.0% 23.7% 24.1% - - - 20.9% 22.3% 22.4% Mature scope Non-mature scope Total 5.0% 5.7% 6.9% FY 2023 FY 2024 H1 2025 Non-mature scope as % of Group sales1 -7.4% -4.9% -2.6% FY 2023 FY 2024 H1 2025 Non-mature scope headwind to Group EBITDA • Mature scope is already approaching our 24% margin target, showing the expected leverage of our established network • Non-mature scope EBITDA headwind has declined in both margin and absolute value, even as sales contribution has increased • Total SDI costs falling – FY 2025 expected to be below 2024, including post-acquisition Spain clinical diagnostics restructuring in H2 1 Non-mature scope growth partly driven by the first-time inclusion of SYNLAB’s clinical diagnostics operation in Spain in Q2 202 5 2 Adjusted EBITDA divided by reported revenues
Page 10
10 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Allocating growth capital with high incremental returns, with minimal external capital requirements 1 Affected by June 2019 cyber-attack 2 Net of treasury shares outstanding 3 Rebased after stock split x10 (11/2020) 4 Calculated as (2024 adj. EBITAS – 2019 adj. EBITAS)/(2024 Capital Employed incl. goodwill – 2019 Capital Employed incl. goodwill) 5 Market cap as of 3 October 2025 20191 2023 2024 H1 2025 CAGR 20193-2024 Adjusted EBITAS (m€) 574 842 1,017 531 +12% Capital Employed (m€) 6,304 8,085 8,338 8,488 +6% ROCE (%) 9.1% 10.4% 12.2% 12.4% - Capital Employed excl. Goodwill (m€) 1,925 2,804 3,000 3,084 +9% ROCE excl. Goodwill (%) 30% 30% 34% 34% - 20191 2023 2024 H1 2025 CAGR 20193-2024 Net Debt (m€) 3,245 2,705 2,996 3,360 -2% Financial leverage 3.2x 2.0x 1.9x 2.1x - Diluted weighted average shares outstanding2 (k) 186,460 3 197,852 194,513 188,509 +1% Balance Sheet Returns 2019-2025 YTD Dividends paid: €775m Share repurchases: returned €858m by acquiring 16.7m shares at an average price of €51.30/share Shareholder remuneration Capital discipline: ~22% return on incremental capital4 2019-2024 (incl. goodwill on acquisitions) Healthy balance sheet maintained, with minimal external capital requirements Cash returned to shareholders: >€1.5bn since 2021, ~13% of market cap5
Page 11
11 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Moving to self-financing of all needs, by increasing cash conversion and disciplined use of capital FY 2023 €m FY 2024 €m Δ €m Δ% Reported EBITDA 1,234 1,439 Change in net working capital (NWC) -65 44 Income taxes paid -140 -161 Other effects1 -12 -4 Net cash provided by operating activities 1,018 1,319 +301 +30% Net operating capex -392 -365 Free cash flow to the firm (FCFF) before investment in owned sites 626 954 +328 +52% Investment in owned sites -152 -154 Free cash flow to the firm (FCFF) 474 801 +326 +69% Lease repayments -181 -192 Interest2 -69 -98 Free cash flow to Equity (FCFE) 225 510 +285 +127% Earnings paid to hybrid capital investors -42 -54 Free cash flow to shareholders 183 457 +274 +150% Dividend -193 -98 Acquisitions net of proceeds from disposals -151 -344 Net cash flow of the period before any refinancing and share buy-back -161 14 Issuance of share capital 8 0 Purchase of treasury shares, net -56 -272 Net cash flow of the period before any refinancing -209 -258 1 Transaction costs and income related to acquisitions, changes in provisions employee benefit obligations and other non -cash effects 2 Net interest (paid and received) and change in investment and financial assets • Eurofins was self-financing before share buybacks in 2024, with improvement across profitability, working capital, capex, and owned-site investments • One-time purchase of related party- owned sites to add minimally to leverage in 2025, with net impact of transaction on leverage ratio expected to be less than 0.2x • Further progress on underlying levers still evident in 2025: • Free Cash Flow to the Firm before investment in owned sites expected to improve over 2024 • Year-on-year improvement in NWC ratio (-80bps) and capex ratio (-40bps) delivered in H1 2025 Self-financing of all needs in 2024, before share buy-backs
Page 12
12 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Credit profile remains strong and maturities extended through successful long-term refinancings Debt maturity profile2 (€m) 1 Leverage: net debt / PF12M adjusted EBITDA (corrected for the estimated impact of the cyber-attack in 2019) 2 Maturity profile as of 30 June 2025 Key Highlights Eurofins’ balance sheet remains very solid as of the end of June 2025: • Financial leverage1 was 2.1x at the end of June 2025 vs 1.9x at the end of 2024 and well within its targeted range of 1.5-2.5x • Impact on financial leverage ratio from 2 September 2025 acquisition of related-party-owned sites expected to be limited to less than 0.2x; financed by long-term debt • No major refinancing requirements until €302m senior Eurobonds due in July 2026 • Eurofins has access to over €1bn of committed, undrawn mid-term (3-5 years) bilateral bank credit lines Leverage1 206 600 400 175 176 298 319 11 302 600 600 750 2025 2026 2027 2028 2029 2030 2031 2032 2035 Hybrid (1st call) Schuldschein Eurobond 1.6x 1.0x 1.2x 1.5x 1.9x 1.9x 2.0x 1.9x 1.9x 2.1x FY 2020 H1 2021 FY 2021 H1 2022 FY 2022 H1 2023 FY 2023 H1 2024 FY 2024 H1 2025 FY 2027 Target range 1.5x-2.5x FY 2027 objective: towards lower end of the range
Page 13
13 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Mid-term objectives – continued improvement in profitability and cash flow, with lower cost of growth 1 Adjusted EBITDA divided by reported revenues 2 FCFF/Reported EBITDA Revenue growth Margin expansion Higher cash and returns Lower capital intensity Leverage within range • Long-term average organic growth target of 6.5% p.a. and potential average revenues from acquisitions of €250m p.a. over the period consolidated at mid-year. • Adj. EBITDA margin1 objective for FY 2027 of 24%, SDI at the EBITDA level should decline towards about 0.5% of revenues • Progression towards these objectives is likely to be back end loaded, as 2025/2026 will still see very significant spend on operational expenses related to digitalisation, SYNLAB restructuring and acquisition dilution. • Further increases in FCFF, cash conversion2 and ROCE are expected as Eurofins completes its 5-year (2023-2027) investment programme. • Net operating capex is expected to be ca. €400m p.a. Investments to own larger state-of-the-art sites will continue and are assumed to be around €200m p.a. over the 2023-2027 period up to €1bn in total and possibly less, with €384m invested as of H1 2025. • Maintain financial leverage in the range of 1.5-2.5x in the mid-term and intent to gradually bring it down towards the lower end of the range by FY 2027. If needed, potential divestments of non-core ancillary businesses would provide further financial flexibility. These objectives assume the same average exchange rates in the mid-term to FY 2027 as in FY 2024. Actual results for each year will depend on the development of individual end markets, exchange rates, the evolution of inflation and the quantum and profitability of M&A, a mong other factors.
Page 14
14 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Actions have been taken on subjects of greatest importance to Eurofins’ key stakeholders Subjects Actions taken 1 Board composition • Following a shareholder vote at the 2025 Annual General Meeting, Eurofins increased the proportion of independent, non- executive directors on its Board of Directors to 67% by appointing Gavin Hill. • Mr Hill is an experienced international executive with extensive experience in sectors including industrials, healthcare and pharma, life sciences, agribusiness and consultancy. Most recently, he was an Executive Director of the public company Oxford Instruments plc, a leading provider of high technology products and services for research and industry, serving as Chief Financial Officer. 2 Cash accounting • Ernst & Young Paris has performed an additional independent audit of Eurofins’ cash pooling arrangements and cash situation in its consolidated financial statements as at 31 December 2023. • Results of cash audit confirmed Eurofins’ FY 2023 cash balance and the high integrity of its systems and controls. 3 Related party transactions • Following a very high approval (95.6%) at the 2025 Annual General Meeting, Eurofins acquired related-party owned sites of a strategic interest for Eurofins companies on 2 September 2025. • Reasonable valuation of €443m reflects fair market value based on appraisal by independent real estate professional network (CBRE); equivalent reconstruction cost would represent an investment of up to €1bn. • Following the transaction, annualised rent paid to related parties (€36m in FY 2024) is expected to decline to a negligible amount, and eventually to zero once the leases on the few, minor remaining related party-owned sites conclude. • The acquisition has been financed from the proceeds of the senior unsecured Euro-denominated bonds issued on 5 August 2025. The net impact of the transaction on Eurofins’ financial leverage ratio is expected to be less than 0.2x.
Page 15
15 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Summary Financial performance showing return to pre-COVID profit and cash flow trends Demonstrating leverage from volume and personnel costs across regions Subjects of greatest importance to key stakeholders now all resolved Continued strong secular growth outlook in all Eurofins activities; mid-term Biopharma outlook is strong beyond current market headwinds Further margin opportunity from network completion and end of major digitalisation programmes by end 2027, and from maturing of recent investment cycle globally Self-financing through increasing cash conversion, enabling growth investment at high returns, and still returning cash to shareholders
Page 16
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2025. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its affiliates. No part of it may be used, circulated, quoted, or reproduced for distribution outside companies belonging to the Eurofins Group. If you are not the intended recipient of this document, you are hereby notified that the use, circulation, quoting, or reproducing of this document is strictly prohibited and may be unlawful. Photo images on this page are the copyrighted property of 123RF Limited. D www.eurofins.com Food & Feed Testing North American Laboratories Network Sean Murray Senior Vice President Food & Feed Testing North America
Page 17
17 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Our growth in numbers Year Labs FTEs 2000 4 <100 2025 ~50 >2,000 Eurofins Food & Feed Testing National business line has built and operates the best-in-class Hub-and-Spoke network of laboratories in North America Atlanta, GA Batavia, NY (Q1‘26) Battle Creek, MI Chicago, IL (Q2‘26) Columbia, MO Dallas, TX Denver, CO Des Moines, IA Fresno, CA Gordon, NE Idaho Falls, ID Lancaster, PA Los Angeles, CA Louisville, KY Madison, WI Midwest City, OK (‘26) Milwaukee, WI Minneapolis, MN North Platte, NE Omaha, NE Philadelphia, PA Providence, RI Raleigh, NC Salt Lake City, UT Salinas, CA San Angelo, TX (‘26) Toronto, ON Upper New England, NH (Q2‘26) Wenatchee, WA Yakima, WA Yuma, AZ Cincinnati, OH Denver, CO Des Moines, IA Fresno, CA Indianapolis, IN Los Angeles, CA Toronto, ON Wilson, NC Yakima, WA Lancaster, PA Madison, WI Milwaukee, WI New Orleans, LA Ithaca, NY Minneapolis, MNDenver, CO Minneapolis, MN Belleview, FL Los Angeles, CA Madison, WI Madison, WI New Orleans, LA Toronto, ON Des Moines, IA Madison, WI Toronto, ON Fresno, CA Lancaster, PA HUB LABORATORIES SPOKE LABORATORIES
Page 18
18 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. North American 3rd party food testing is a ~$2.8bn market with tailwinds that accelerated through the pandemic • Supplement/Nutraceutical production ~2x market CAGR since pandemic with desire for healthier, functional foods1 • Continued discovery of new contaminants: traditional (heavy metals) and new (PFAS) • Many reformulations coming with MAHA changes NA 3rd Party Testing & Services $ Billion est 2025 0.4 0.4 0.9 1.1 2.8 Chemistry Microbiology Audit & consulting Other services Relevant market trends • General trend towards outsourcing of internal testing (3rd party trust, economics, keeping pathogens out of factory) • Continued recalls, especially in meat and produce • Ex: 5 largest food recalls in history occurred since 20062 • Strong market for food start-ups and plant builds requiring auditing and certification • Tight labor markets encouraging outsourcing (e.g. product design) 1. Eurofins US Food annual client survey 2. https://www.investopedia.com/financial-edge/0512/the-5-largest-food-recalls-in-history.aspx
Page 19
19 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Eurofins is the clear leader in North America because of our differentiated breadth, science and reputationCompetitors Eurofins’ market share1 #1 share Other major players Small local players1 ~2/3 share 1Internal market estimates to the best of Eurofins’ knowledge 2Safe Quality Food 3British Retail Consortium 4Nuclear Magnetic Resonance 5Limit of Quantification (smallest detection limit) 6Association of Official analytical Chemists Example Offerings Microbiology ➢ Most method development, technical support chemists Chemistry Services Science & Reputation ➢ Massive food microbiology laboratory location growth: 5 in 2016, 27 in 2025 ➢ Focus on services that complement testing (e.g., food safety plan consulting) ➢ Continued, differentiated but prudent investment in scientists and facilities Nutritional Including Labeling, Stability and Shelf Life Contaminants Heavy metals, mycotoxins, pesticides Supplements: Identification + Purity Pathogens and Quantitative Filth & Extraneous Matter Microbiome/ Micro speciation Process Validation / Aseptic Packaging Product + Process Design and Consumer Sensory Global Scheme Auditing (SQF2, BRC3…) Industry thought leadership: AOAC6 presidency, heads of many industry boards Consistent innovation leader: lowest LOQ5 contaminants, 1- day vitamins Nearly 100 years of expertise: original vitamin methods, pioneer in NMR4
Page 20
20 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Our market position is strong because of many “nodes” in our network and support systems are difficult to copy • Have built scale of ~50 samples per day from 5+ decades of winning small orders • Very low marginal cost, daily batches • Low desire to switch: high consequences • High repeat orders: re-work 40% to 10% • 27 micro labs + dedicated sales + rep = continued share growth Example: Des Moines Vitamin A Testing
Page 21
21 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Network effects, segment focus, start-ups, and measured, effective acquisitions lead to market++ profitable growth North America Food & Feed Testing revenues • Covance acquisition yielded instant leadership in supplements, a segment very accretive to growth • Covance provided footprint and scale to execute our start-up programs • Over a dozen start-ups since 2017 have added 2-3% CAGR on the entire business - 50 100 150 200 250 300 350 400 450 500 2018 (pro-forma) 2019 2020 2021 2022 2023 2024 2025E Eurofins Covance (in year of acquisition) Covance Food Sol. acquisition
Page 22
22 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Capex needs are lower and falling with hubs complete; cash improvement amplified by labour productivity gains • When we hit capacity points we use lean, automation and digitalization to avoid hiring or reduce FTE – headcount is broadly flat since 2023 • We also get natural scale effects as we add samples at high contribution margin 150000 170000 190000 210000 230000 250000 270000 0 50000000 100000000 150000000 200000000 250000000 300000000 350000000 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025E Revenues Revenues/FTE 0% 5% 10% 15% 0 50000000 100000000 150000000 200000000 250000000 300000000 350000000 400000000 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025E Revenues Capex/Revenues (RHS) • Hubs required large one-time capex for footprint, HVAC, and new instrumentation • Needs become lower with complete network: ~5ppt fall in hub capex since 2018, similar improvement in total capex • Continued growth required for incremental equipment and as utilities wear out Decreasing capex/revenues Increasing revenues/FTE 57% increase in revenues/FTE 2016-25E 2020 increase due to Madison investment
Page 23
23 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Significantly enhanced productivity of Food & Feed Testing laboratory footprint 2020 2021 2022 2023 2024 2025E 2020 2021 2022 2023 2024 2025E U.S. Food & Feed Testing: Revenue per sqm 64% increase 2020-25 U.S. Food & Feed Testing: Sqm footprint/FTE 21% decrease 2020-25 • Better utilization of laboratory space has allowed lower capex intensity without compromising on growth potential • Revenue growth since 2020 has been delivered in a largely unchanged overall footprint, due to consolidation of the laboratory network while maintaining full market coverage • Productivity has been further enhanced by focusing on sweating existing assets before investing in expansion, shown by falling footprint per FTE
Page 24
24 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Start-ups continue to provide growth, with the latest ones reaching profitability more quickly We have been able to add start-ups that grow, even as we gain share… …and we have become much better at returning investment quickly Revenue by year, since lab opening EBITDA by year, since BU start Break-even even faster after lab opening which is 6 -12 months later Break-even
Page 25
25 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Better matching of facility and market requirements has greatly reduced break-even timing for spoke investments • Rented small facilities with existing HVAC; or Modular lab that is factory built instead of built in place with design/build contractors. Result is lower cost / sqm • Anchor client year 1 volume of ~20% of capacity and Eurofins now known in microbiology Omaha Spoke • Start-up in 2025 • Net floor area: 500 sqm • Break-even: months Louisville Spoke • Start-up in 2017 • Net floor area: 835 sqm • Break-even: years
Page 26
26 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Accretive acquisition opportunities are also available as PE firms exit: Barrow Agee is a good example Investment* Net Sales EBITDA How is it possible to acquire a company that was losing money with negative ROI… …which becomes a good investment for Eurofins? Investment Net Sales EBITDA Private Equity Owned Eurofins Owned *Acquisition price + capex and integration cost *16% Yr 2 ROI achieved & further ROI growth expected from sales & productivity increases >10% higher than under PE ownership Margin: -10% Margin: >30%* ~3x less than purchase price paid by PE
Page 27
27 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Scale and test overlap enable high ROI consolidation Key facets of the target company which enable incremental cash flow inside Eurofins: ✓ Ownership which cannot extract value from scale…. • Barrow Agee owned by Private Equity for 4 years, lost #1 client from loss of founder • Single site, dedicated management team and too wide test portfolio: Prox / Micro / Pesticides / Residue ✓ …but enough scale at Eurofins’ hub laboratory to allow automation and LEAN benefits after consolidation • Hundreds of samples per day combined with Eurofins’ existing business to make thousands / day • 57 FTE as stand-alone → 30 FTE in Eurofins ✓ Test portfolio fits into Eurofins laboratories with little investment • Matrices (Animal Food) and Assays (AOAC ref methods) nearly identical to our 7x larger laboratory ✓ EBITDA of company prior to acquisition by Eurofins near zero or negative • Strong EBITDA will attract financial buyers and leverage, drive multiple up ✓ Acquisition dilutive to ROI in Year 1 but very accretive from Year 2
Page 28
28 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. • Hyper local microbiology laboratories (e.g. meat/produce/supplements) • Retailer supplements support: testing, certification for thousands of suppliers Performance area One-stop shop coverage Only in-class turnaround time Disruptive technologies • From ~14 day worst case turnaround; to most at ~7 days, and all below 10 days • <1 week any assay imaginable in next two years • Options for same day test: modular locations, super rapid assays • Continued first to market in nutrients, emerging contaminants (PFAS) • Supercritical fluid extraction: extremely high volume, low handling technique for vitamins analysis Extreme quality at scale • Client response monitoring with <4-hour response 99% of time • 100% online ordering: reduce faults, enable data consumption • Home for talent: GMs and top chemists/microbiologists • Enable high synergy consolidations opportunistically We expect continued above-market growth with speed, and quality standards hard to match without our scale
Page 29
29 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Summary Operating best-in-class Food & Feed Testing laboratories network in N. America Provide most comprehensive offering, and deliver above-market growth from hard-to-copy network Market leadership Accelerate sales from start-up programs, and prudent M&A Disrupt industry even further, setting new standards for food testing Drive returns through completed hub network, with lower capex and FTE needs for growth
Page 30
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2025. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its affiliates. No part of it may be used, circulated, quoted, or reproduced for distribution outside companies belonging to the Eurofins Group. If you are not the intended recipient of this document, you are hereby notified that the use, circulation, quoting, or reproducing of this document is strictly prohibited and may be unlawful. Photo images on this page are the copyrighted property of 123RF Limited. D www.eurofins.com Eurofins Environment Testing U.S. Brian Williams Group Executive Vice President Environment Testing (North America) Regional & Multi Business Lines (APAC) International Business Line - Environment Testing
Page 31
31 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Agenda US Market Overview Eurofins Environment Testing in the U.S. Macro Trends Market Overview Market Drivers Locations & Organizational Structure Geographic Orientation – Hub & Spoke Model PFAS Orientation, Investment & Evolution Sector/Segments/Clients Growth & Margin ESG Participation Scorecard Digitalization What’s Next?
Page 32
32 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. US Market Overview
Page 33
33 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. U.S. Environment market overview Env. Sectors Env. Testing Sources: EBJ 2024 and Company Estimates (2024 Data) 48% 16% 37% Services Equipment Resources Management WWTW (Wastewater Treatment Works) Analytical Consolidated Waste Management Remediation Consulting & Engineering (C&E) ~$2.3B$537B USEPA enacted budget $9.2B (<2% of sector spend) Eurofins Env. Testing U.S. Circa 30% of market to be consolidated Other majors circa 45% Testing ~5% of Consulting & Engineering Env. Services $80.7B $111.2B $44.6B $17.1B $2.3B $256B Testing ~1% of services U.S. C&E is 42% of global
Page 34
34 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Environment Testing Market Drivers Environmental Impact, Social & Corporate Responsibility/Governance ESG underpins the market for measuring Environmental Impact, Social Responsibility and Governance Practices. Demand for measurement of corresponding metrics translates to demand for testing. Litigation Litigation refers to legal action or lawsuits, driving the need for defensible data related to environmental matters. Regulatory/Political Regulatory and Political drivers are the laws, rules, and policies that compel companies and agencies to meet environmental standards, thereby increasing demand for testing. Market drivers
Page 35
35 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Federal funding is in the spotlight, but expected Defense PFAS spend is rising, and EPA spend is <2% of sector FY25 Requested Budget: • $850M FY26 Requested Budget: • $273M • + $135M added by Senate appropriators citing concerns over drinking water contamination Department of Defense - PFAS Estimated Requested • Overall budget cut by $4.9B, Operating budget by $1B • $1.47B in funding is proposed for elimination across various grants/programs. Key areas affected: environmental education, pollution control, and air quality management. • A reduction of $1.5B for the Clean Water State Revolving Fund with an emphasis on state responsibility for funding local environmental programs. EPA budget being cut, but represented <2% of US Env. Sector Spend in 2024 1GAO: Government Accountability Office 2DoD: Department of Defense GAO1 reported in February 2025 that DoD2 estimated future costs for PFAS investigation and cleanup have more than tripled since 2022, reaching over $9.3 billion for FY2025 and subsequent years. Current budget being cut… …but expected PFAS costs rising
Page 36
36 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 2025 Administration agenda prioritises economic growth, with some new testing opportunities KEY REGULATORY ACTIONS BUSINESS IMPACT ASSESSMENTFIVE PILLARS OVERVIEW Clean Air, Land & Water Maintain environmental protection while being cost-conscious and supporting economic growth American Energy Dominance Cut energy costs, reduce foreign dependency, streamline energy production regulations Permitting Reform & Federalism Streamline approval processes, shift authority to states, encourage business investment AI Capital Leadership Remove barriers for data centers and semiconductor manufacturing facilities Auto Manufacturing Revival Reduce regulatory burden on automotive industry, bring back domestic jobs Climate & GHG Regulations • Reconsider 2009 Endangerment Funding • Overhaul Social Cost of Carbon methodology • Review Clean Power Plan 2.0 • Revise GHG reporting requirements Air Quality Standards • Revisit particulate matter (soot) standards • Restructure Regional Haze Program • Reconsider Good Neighbor Plan • Review 8 industry NESHAP standards Water & Waste Regulations • Revise WOTUS definition • Modify steam electric discharge standards • Transfer coal ash oversight to states • Revise oil & gas effluent guidelines Permitting & Enforcement • Streamline air permitting processes • Realign enforcement priorities • Clear SIP/TIP backlogs • Reduce energy production burdens Compliance Testing Demand Regulations drive our core business regardless of stringency. Relaxed standards may reduce testing frequency but compliance verification remains essential. Delayed Implementation Coal Combustion Residuals delays, Mercury Air Toxics Studies exemptions, and extended compliance deadlines could defer some revenue streams from affected facilities. Remediation Market Site investigation and remediation services likely unaffected - contaminated sites still require cleanup regardless of regulatory approach. State & New Sector Opportunities Shift creates opportunities as states develop programs requiring compliance. AI/data centers & semiconductor mfg emphasis may create new testing opportunities. Low Impact Neutral Opportunity Sources: https://martenlaw.com/news/cost-reduction-underlies-epa-regulatory-rollback https://www.reginfo.gov/public/do/eAgendaMain WOTUS: Waters Of The United States; NESHAP: National Emission Standards for Hazardous Air Pollutants Low Impact
Page 37
37 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Eurofins Environment Testing in the U.S.
Page 38
38 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Eurofins Environment Testing Laboratories Network USA 550+ Accreditations & Certifications ~3,200 Staff (2024) 74 Laboratory locations
Page 39
39 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Investing in Network Growth to drive Productivity Chicago 35K sq ft New Build, Relocation COMPLETE Sacramento 68K sq ft New Build, Relocation 2027 Houston 48K sq ft New Build, Relocation Q1 2027 Lancaster 86K sq ft Expansion, Renovation Q3 2027 Denver 58K sq ft Renovation 2027 South Bend 73K sq ft Expansion, Renovation Q4 2025 Concord 30K sq ft Expansion, Renovation Q2 2027 Rhode Island 15K sq ft Expansion, Renovation Q4 2027 Edison 42K sq ft Renovation Q1 2026 Cherry Hill 12K sq ft New Build Q4 2025 Atlanta 41K sq ft Renovation Q3 2026 Pensacola 28K sq ft New Build, Relocation Q3 2026 St. Louis 34K sq ft New Build, Relocation Q4 2026 13 laboratories expansion/relocation to state-of-the-art site projects completed 2025 or scheduled Q4 25, 26/27
Page 40
40 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Eurofins Environment Testing U.S. Geographic Orientation + Hub & Spoke model Drinking Water & Wastewater Laboratories Hubs Pomona, CA South Bend, IN Orlando, FL Concord, NH Built Environment Testing Laboratories Distributed Model 26 locations Chicago, IL Houston, TX Atlanta, GA Regional CentersSpecialty Hubs WEST CENTRAL EAST Contaminated Site & Remediation Laboratories Sacramento, CA Denver, CO St. Louis, MO National Hubs Lancaster, PA Tustin, CA
Page 41
41 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 7 PFAS Testing Hubs 25 yrs of PFAS Testing experience >100 instruments dedicated to PFAS 130+ compounds in dozens of matrices >50K samples/month capacity >1.1M PFAS samples analyzed Largest PFAS testing laboratory network in the US: Scale, Efficiency and Technical Leadership • Eurofins is the global leader in PFAS Biomonitoring testing, including the largest PFAS epidemiological study ever conducted. >12,000 samples analyzed in Belgium >20 PFAS health research studies supported in the U.S. in the past 18 months. • First to market with comprehensive PFAS Forensic capabilities including Forensic PFOA, Ion Mobility, and Non-Target Analysis (NTA). Lead collaborator with EPA on std method for NTA. Co-authored multiple papers on Forensics and leading a Forensics working group. • Lead developer/collaborator with EPA on “Other Test Methods” OTM-45 & OTM-50 for PFAS in source air emissions. First to market with OTM-50. • Eurofins has global partnerships with multi- national industrial clients and consultants to support their PFAS programs worldwide. Eurofins industry technical leadershipEfficiency: PFAS samples processed at Eurofins USA laboratoriesLeading scale in US PFAS testing
Page 42
42 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Addressing PFAS: evolution of the science PFOA & PFOS 7 PFAS 40 PFAS 75 PFAS 100 PFAS TOP1 Assay TOF2 NTA3 An ever-expanding number of matrices/substrates under investigation and an ever-expanding number of technologies (investment) to make identifications 1TOP: Total Oxidizable Precursors 2TOF: Total Organic Fluorine 3NTA: Non-Target Analysis
Page 43
43 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Broad-based revenue profile across tests, industries and customers Sources: Company Estimates Diversified customer mix Net sales by sector 16% 66% 18% Industry Direct Consulting Engineers Direct Government 15% 9% 9% 67% Client #1 - 10 Client #11 - 25 Client #26 - 50 Remainder of Clients 21% 66% 13% Drinking Water and Wastewater Contaminated & Remediation Sites Built Environment Net sales by market segment ~17,500 clients >15% YoY sales growth for top 25 clients Key highlights • Diverse client base across test types and industry verticals • Multiple relationships with Fortune 500 & Fortune 1000 customers • +38% CAGR in PFAS Clients over the last 3 years Top 50 Clients 33% of Net Sales
Page 44
44 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Tailwind and strategy for accelerating revenue growth Data normalized for divested/exited sectors US Environment Testing Network Strong revenue growth 6-year Organic Growth CAGR +7.5% • Leader position in largest Environment Testing market in the world (Market Estimate $2.4 pa @ 2025*) • >100% total growth over past 6 years (~2/3 of which is organic) • +7.5% organic growth CAGR between 2019 and 2025 • Organic growth outstrips acquired growth by 2:1 • Organic growth supported by bolt-on acquisitions, their complementary capabilities, and geographies • 31 Acquisitions post TestAmerica in November 2018 *Source: EBJ 2024
Page 45
45 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Hub & Spoke Model: The Engine that Powers Margin Accretion HUB SPOKE 10% 28% 6-year Net Sales CAGR 6-year EBITDA CAGR Key Trends 6% 15% 6-year Net Sales CAGR 6-year EBITDA CAGR Net Sales (2019 → Inner circle) (2025 → Outer circle) ‘19 Act → 40% ’25 FCT → 45% % of Net Sales from Hub Labs EBITDA (2019 → Inner circle) (2025 → Outer circle) ‘19 Act → 40% ’25 FCT → 55% % of EBITDA from Hub Labs
Page 46
46 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Operational Improvement Driving Margin Accretion Consumables Other Key drivers of savings+1200bps of margin expansion from 2019 to 2025F Personnel • Productivity via automation • IT process streamlining • Consolidation of workstreams Consumables • Centralized procurement • Method optimization • Kan Ban / waste reduction Other • Site consolidations/Service centralization • Hub & spoke • Energy efficiency • Logistics management Cost/Sales Ratio
Page 47
47 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Service leadership = market share: Turnaround Time performance 0 20 40 60 80 100 2022 2023 2024 2025 TAT-50 TAT-95 60% improvement in 95th percentile turnaround time 40% improvement in median turnaround time Turnaround time for reporting results on 50% and 95% of samples, indexed to 100 in 2022
Page 48
48 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Positive ESG Initiatives – Participating and Saving Voluntary Employee Turnover Fully operational dedicated Center of Excellence focusing on robotics, AI, Lean and automation Tustin = In Permitting Pomona = In Permitting Barberton = Awarded & In Design Rhode Island = In Scoping Dallas (BioAquatics & Radon) = In Place Lancaster (30%) Houston (50%) South Bend (50%) Corpus (100%) Cedar Falls (56%) Dallas (BioAquatics & Radon) (over 50%) 40+ other sites eligible and in review LTM August 2023 to 2024 – 110 bps Improvement LTM August 2024 to 2025 – 300 bps Improvement ~400 bps Improvement over 2 years Solar Initiatives Green Energy Contracts 15000 35000 55000 75000 2022 2023 2024 Total Learning Hours Total Courses Complete Center of Excellence Microextractions Learning Stats Number of Learners Since 2022 53% 0% 5% 10% 15% 20% 25% 30% 35% 0 20 40 60 80 100 120 140 2022 2023 2024 H1 2025 Number of Samples / Liters (Indexed @ 100) DCM Utilization vs.number of SVOA samples Soil Samples Water Samples Liters of DCM % Water Microextractions
Page 49
49 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Sample Lifecycle Digitalization: Sampling to Reporting Eurofins Environment Testingjoined EarthSoft Business Partner Program, aligning with EQuIS digital workflows. Mobile optimized eCOC and sampling • Secure, web-based entry from mobile or desktop. • Guided forms, dropdowns, and reusable templates for easy submission. • Direct integration with LIMS for automated sample receipt and tracking. • Reduces errors, accelerates login, and streamlines processing. Client Data Management Portal • Reviewed results auto-uploaded for timely, consistent access. • Displays data vs. regulatory limits, flags exceedances, and tracks compliance. • Offers trend charts for current and historical results. • Self-service access reduces support needs and improves client satisfaction. Tools for self service Standards & Governance Standardized EQuIS workflows improve data quality & completeness. Protocols for data submissions, analytes, methods, users, locations. Completed Integrations eQuote: Quotes aligned with client sampling plans (EQuIS compatible). eCOC (Electronic Chain of Custody): Streamlined sample login by analyte, method, and holding time. EDD (Electronic Data Delivery): Results in standardized EQuIS formats. Coming Soon eSRN: Sample Receipt Notification from lab. Invoice Submission: Sent in eSRN format.
Page 50
50 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Automated Intelligent Data Quality for Review & Report Delivery = Efficiency & Productivity Data Review Checker Enhanced data integrity by automating the detection of inconsistencies and utilizing a dual-review processes. Automated Checks: Real-time validation against predefined rules. Flags anomalies, gaps, and outliers. Analyst Alerts: Instant notifications on flagged issues. Reduces manual review and accelerates resolution. Post-Review Automation Client Deliverables: Electronic Data Deliverables (EDDs), reports, & invoices consistent and complete documentation. Seamless Distribution: Sends packages to client contacts. Supports multiple formats and secure transfer. Efficiency Gains: Reduces manual effort and turnaround time. Minimizes risk of delays or omissions. Audit & Traceability: Logs delivery & confirmations. Ensures compliance & QA/QC support. Automatically compiles deliverables once lab data is approved.
Page 51
51 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. What’s Next?... Microplastics (6 Centers Globally) • US: Morphology based technology Instruments: Raman Spectroscopy & Infra Red (IR) • EU: Mass based technology Instruments: GC-pyrology • APAC: Morphology based technology Instruments: Laser Detect Infra Red (LDIR) Fourier Transfer Infra Red (FTIR) Compliance Testing • Wastewater Treatment Plants as clients • B2C kits for standard water testing, PFAS in Water, PFAS in Blood Passive Sampling • PCBs, OC Pests, PAHs, PFAS Non-Target Analytes • High demand to understand the future emerging contaminants
Page 52
52 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Summary Long-term GDP+ growth profile, with attractive market structure and diverse customer base Well positioned to capture ongoing PFAS opportunity, with established scale, process efficiency and technical leadership Apolitical focus on sustaining regulation and growth, and includes some additional opportunities Driving margin via a hub and spoke network and operational improvements; with more leverage to come from further network expansions Further areas of opportunity emerging, including microplastics
Page 53
CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd, 2025. All rights reserved. This document contains information that is confidential and proprietary to Eurofins Scientific SE and / or its affiliates and is solely for the use of the personnel of Eurofins Scientific SE and all its affiliates. No part of it may be used, circulated, quoted, or reproduced for distribution outside companies belonging to the Eurofins Group. If you are not the intended recipient of this document, you are hereby notified that the use, circulation, quoting, or reproducing of this document is strictly prohibited and may be unlawful. Photo images on this page are the copyrighted property of 123RF Limited. D www.eurofins.com BioPharma Services Timothy Oostdyk Executive Vice President BioPharma, Genomics and Agrosciences Services North America
Page 54
54 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Leading Global BioPharma Network Eurofins BioPharma Services location map as of October 2025 North America Europe Rest of the World 3 laboratories 20 laboratories 38 laboratories 89 laboratories ~192,000 m2~137,000 m2 ~65,000 m2 Leader in significant markets 147 laboratories in 35 countries ~390,000 m2 laboratory capacity • Global leader in BioPharma Product Testing • Global leader in Discovery Pharmacology Services • Global leader in Agroscience CRO Services
Page 55
55 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. BioPharma Services evolution BioPharma Product Testing2006 Discovery Pharmacology2012 Genomic Services2005 Central Laboratory / Bioanalytical2001 CTDMO Services2017 Started Select milestones / acquisitions Market position today Among top 5 global players Among top 5 global players Global leader since 2011 Global leader since 2012 2011: Global infrastructure established (US, Netherlands, Singapore, China, India) Acquisitions: Acquisitions: Acquisitions: Acquisitions: Discovery & Development Solutions Acquisitions: Integrated Discovery Services2020 Medical Device Testing2007 Acquisitions: Acquisitions: 2020: all global Eurofins Discovery sites integrated together as DiscoveryOneTM Emerging player Medical Device Services2022 Acquisitions: 2022: significantly expanded service offering into Packaging and Sterilisation of medical products Among top 5 global players Agroscience Services2006 Acquisitions: Global CRO leader since 2017
Page 56
56 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Eurofins BioPharma services span the complete product development cycle DISCOVERY PRECLINICAL / EARLY DEVELOPMENT CLINICAL RESEARCH & DEVELOPMENT APPROVAL COMMERCIAL Lead Qualification Synthesize NME or New Biologic Assess Safety and Biological Activity Pharmacology, Toxicity & DMPK Assess Safety. Dosage & Efficacy in Humans Phase I, II and III Studies Verify Safety, Effectiveness & Controls to Agency Assess Long-Term Effectiveness (Phase IV Studies) Surveillance/Quality Control DISCOVERY: Modeling, Screening & Characterization, Chemistry, Potency, Selectivity, Safety, ADME, Toxicity, Efficacy, Custom Assays PRECLINICAL / EARLY DEVELOPEMNT: Toxicology, Safety Pharmacology, Analytical Services CDMO: Drug Substance/API & Drug Product Development & Manufacturing for Biologics and Small Molecules BIOPHARMA PRODUCT TESTING: GLP, GMP, Stability, Quality Control, Microbiological Testing, Process Development PSS: Hiring, training and managing insourced scientists and related support staff at Client facilities GENOMICS: Next Generation Sequencing, Genotyping, Micro Arrays, Pharmacogenetics BIOANALYTICAL: Bioavailability, PK/TK, Immunogenicity, Nab, Biomarkers, Bioequivalence EARLY CLINICAL DEVELOPMENT: Clinical Pharmacology, Global Clinical Trials, Biometrics CENTRAL LABORATORY: Safety, Biomarkers, Bioanalysis. Infectious Disease Services SPECIALTY CLINICAL TRIAL LABORATORY: Infectious Disease & Molecular, Immune Response, Allergy/Hypersensitivity ANATOMICAL PATHOLOGY: Over 2,500 assays: [Molecular] Pathology, Histology, Cytology, FISH File IND File NDA, BLA, MAA Launch Product PRODUCTCLINICAL
Page 57
57 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Clients & PeersClients1 Peers Typical contractual relationship: ➢ Product Testing: annual master service agreements ➢ Research & Development Services: project-based agreements 1 Examples of typical clients shown for illustrative purposes only Major Biopharma companies Innovative biotech + regional & local players + regional & local competitors
Page 58
58 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Market Update
Page 59
59 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 9,605 9,737 9,713 10,452 10,479 11,307 12,300 13,718 14,872 15,267 16,181 17,737 18,582 20,109 21,292 22,825 23,875 0 5,000 10,000 15,000 20,000 25,000 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Drug Count Biological Non-biological (chemical, natural, etc.) Robust long-term demand drivers: growth in R&D pipelines, and mix shift to higher-value biologics Source: Pharmaprojects, January 2025. Long-term growth in number of Biopharma projects is ahead of GDP, driven by intensity & speed of innovation Value per project also increases over time, as mix shifts favourably: • Testing requirements for Biologics and new therapies are ~4-10x higher than for small-molecule chemical drug candidates • Higher value molecules and more personalised care means more potential for customized and higher-value services 2025 pipelines show positive trends continuing, both in overall project growth and favourable mix shift Opportunity for Eurofins Total industry R&D pipeline size ~6% CAGR in # of candidates 2009-25
Page 60
60 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Total R&D Spend Spend with Eurofins Eurofins has been also able to increase share of R&D wallet, and grow revenue above total spending BioPharma client R&D spend1: Data for 5 key clients, indexed to 2015 1 Based on aggregate data for 5 Eurofins clients, sourced from Eurofins and public sources, in US dollars. R&D spend data exclu des disclosed in-process R&D and M&A-related charges. 7.6% CAGR total R&D spend 10.8% CAGR spend with Eurofins Increased share of wallet reflects long-term trend to more outsourcing of R&D services • Pressure on industry to reduce fixed cost bases despite increasing complexity • Externally available infrastructure and capabilities = more speed and agility, and less capital employed • Enables access to scientific & regulatory expertise, experience and competencies that are difficult & expensive to insource Eurofins’ range of services offered to clients is increasing over time • Addition of CDMO services, integrated discovery services and medical device services since 2015 • Expanded geographic coverage supported by integration of 2024 acquisition of Infinity Laboratories 100 100 279 209 Drivers of increased share 2024 reflects previously disclosed clinical trial discontinuations at major customer – overall BioPharma revenue grew 2%
Page 61
61 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Biopharma segments: Strong growth in largest part of portfolio; easing comps into 2026 for smaller businesses ~25% ~20% ~15% ~15% ~60% ~65% H1 2023 H2 2023 H1 2024 H2 2024 H1 2025 Global BioPharma revenues Organic growth H1 2024 H2 2024 H1 2025 BioPharma Product Testing and others1 ~ +4% ~ +5% ~ +6% Discovery and Genomics ~ +4% ~ -2% ~ -4% Ancillary activities ~ 0% ~ -15% ~ -10% Total BioPharma +2.6% -0.9% +0.8% €m Ancillary activities2 • Recent slowdown reflected multiple factors including mid-2024 early end of several successful clinical trials in Central Laboratory/BioAnalysis; reductions in client R&D spending on agrochemicals • Canada CDMO business has remained strong, with double-digit growth as investments from last 5 years ramp up • Going forward, larger programmes are in our Central Laboratory pipeline and are awaiting initiation; refocusing resources in Agroscience and CDMO ex-Canada; easier prior year comparators from Q4 2025 Discovery and Genomics • Discovery affected by muted early-stage spending by biotech clients; Genomics impacted in North America by reduced government funding for research • Easier comparators into 2026, as we lap the slowdown of the last 12 months; Biotech industry awaiting clarity on short-term funding outlook BioPharma Product Testing and others1 • Organic growth accelerated in H1 2025, with solid growth in North America as Eurofins companies support customers investing in pipeline candidates • Further progress from integrating 2024 Infinity Laboratories acquisition, supporting expanded geographic coverage of services offered • Long-term drivers expected to continue, with growth of pharmaceutical pipelines, evolving mix towards higher-value modalities, and increased outsourcing by clients 1,0421,0101,000995976 Commentary 1 Includes activities related to BioPharma Product Testing (i.e., Professional Scientific Services) and Forensic Services 2 Includes Central Laboratory, Bioanalysis and Toxicology; Agroscience Services; and CDMO businesses
Page 62
62 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Delivering Value to our Clients
Page 63
63 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Industry continues to make major investments, with onshoring drive creating opportunities for Eurofins • Multiple Pharma and Biotech manufacturers have announced major US investment programmes, with a backdrop of political support and potential pharmaceutical tariffs • Trend to reshoring brings opportunities for outsourced services: facility validation requires significant testing away from the facility, metrology and calibration, and raw materials testing • Eurofins is already a leading provider in these categories, with sites in key regions for the Biopharma industry 21 March 2025 Announced manufacturing, research and development, and technology investments of more than $55 billion in the United States over the next four years 10 April 2025 Announced planned $23 billion investment over 5 years in US- based infrastructure, ensuring all key Novartis medicines for US patients will be made in the United States 7 May 2025 Announced total investment of $32 billion in US manufacturing and R&D through 2030 23 September 2025 Announced plans to build a new $6.5 billion manufacturing facility at Generation Park in Houston, Texas https://www.jnj.com/media-center/press-releases/johnson-johnson-increases-u-s-investment-to-more-than-55-billion-over-the-next-four-years https://www.novartis.com/us-en/news/media-releases/novartis-plans-expand-its-us-based-manufacturing-and-rd-footprint-total-investment-23b-over-next-5-years https://www.gilead.com/company/company-statements/2025/gilead-us-investment-to-create-43-billion-value-to-us-economy https://investor.lilly.com/news-releases/news-release-details/lilly-plans-build-new-65-billion-facility-manufacture-active Examples of Biopharma industry onshoring announcements
Page 64
64 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. BioPharma Product Testing Footprint Strategy in North America • >4,000 addressable customers in the US • We currently service 1,200 • Smaller regional customers value local relationships and nearby access to the laboratory • Infinity Laboratories acquisition and plans to open smaller regional sites will accelerate the capture of this segment of the market Heat map of addressable customers for BioPharma Product Testing
Page 65
65 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Eurofins Discovery provides a wide portfolio of solutions for Obesity and Diabetes discovery and development Offering: Eurofins Discovery obesityLITE Panel of Cell Based Assays • The obesityLITE panel contains 25 relevant assays for cellular targets with important roles in the gut-brain signaling axis Eurofins Discovery is currently working on over 40 client programmes supporting obesity drug discovery and development through a variety of solutions designed for assessing the key obesity targets Müller, T.D., Blüher, M., Tschöp, M.H. et al. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov 21, 201–223 (2022). https://doi.org/10.1038/s41573-021-00337-8 5.6 7.2 9.1 11.6 14.7 18.7 23.7 30.1 38.3 48.6 61.8 78.5 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Solutions for a high-growth category: Anti-obesity drugs market size projection 2023-2034 (US$ billion) Source: towardshealthcare.com
Page 66
66 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. CDMO capacity and capability expansion: to provide fully integrated services offering Toronto Large Scale API Manufacturing Expansion • 1st plant completed 2024. Multiple 2,000L reactors installed • Plant capacity is nearly fully sold for next several years • Site can accommodate two additional plant expansions. 2nd plant in active planning phase • Addresses late-stage clinical & commercial demand Toronto Campus Buildout • 112,000ft2 expansion, to be completed H2 2026 • Biologics manufacturing & expanded laboratories • BioPharma Product Testing Laboratories • Co-located with CDMO, offering additional synergies & offering Biologics (mAbs & therapeutic proteins) • Government funding support • Development facility operational Jan 2024 • Multiple 2,000L Bioreactors & Sterile Fill facility, to open in H2 2026 Integrated Antibody Drug Conjugate (ADC) capability • Site has 15-year site history in Linkers & HPAPI • New offering: Conjugation (mAb + Linker/HPAPI) • Unique offering with all capabilities “under one roof”
Page 67
67 CONFIDENTIAL AND PROPRIETARY - © Eurofins Scientific (Ireland) Ltd [2025]. All rights reserved. Any use of this material without the specific permission of an authorized representative of Eurofins Scientific (Ireland) Ltd is strictly prohibited. Summary Attractive long-term demand drivers of therapeutic innovation, with increasing mix of higher value categories Solid organic growth continuing in Product Testing and CDMO; comparators easing in Ancillary and Discovery & Genomics Trend to increased outsourcing has driven growth above total customer R&D spend Additional opportunities emerging, including supporting onshoring, obesity/diabetes, and expanded CDMO opportunity Well positioned to capture market recovery with state-of-the-art, fully-digitised laboratories, with globally standardised processes; QA & IT solutions and strategic service offerings